ELMS STEVE
ELMS STEVE's purchase track record
ELMS STEVE has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/5/2026 | ADMA | $217K | -49.2% | -39.0% | +13.4% |
| 12/23/2024 | MRKR | $35K | -62.6% | -58.5% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Marker Therapeutics appears in Yahoo's October 16 top picks. Yahoo included Marker Therapeutics in its list of notable stocks for October 16. The mention may increase visibility among investors. The stock is currently near its $1.41 support level and has an RSI of 38.5, suggesting modest momentum.
Transaction History
| ADMA | ▲ Buy | Open Market | 7,000 | $108K | 3/6/2026 | View on chart |
| ADMA | ▲ Buy | Open Market | 7,000 | $110K | 3/5/2026 | View on chart |
| ADMA | ▲ Buy | Grant | 10,690 | $0 | 2/9/2026 | View on chart |
| ADMA | ▼ Sell | Open Market | 194,749 | $3.9M | 6/16/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 9,000 | $54K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 10,000 | $50K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 53,837 | $197K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 17,500 | $86K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 30,000 | $117K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 15,000 | $44K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 37,541 | $203K | 6/13/2025 | View on chart |
| ADMA | ▼ Sell | Open Market | 137,931 | $2.9M | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 55,000 | $129K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 53,172 | $89K | 6/13/2025 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 51,630 | $173K | 6/13/2025 | View on chart |
| ADMA | ▼ Sell | Open Market | 92,941 | $2.0M | 6/12/2025 | View on chart |
| ADMA | ▲ Buy | Grant | 10,889 | $0 | 2/19/2025 | View on chart |
| MRKR | ▲ Buy | Open Market | 11,085 | $35K | 12/23/2024 | View on chart |
| ADMA | ▲ Buy | Option Exercise | 9,000 | $97K | 11/27/2024 | View on chart |
| ADMA | ▼ Sell | Open Market | 411,829 | $2.5M | 3/19/2024 | View on chart |
| ADMA | ▼ Sell | Open Market | 49,887 | $300K | 3/18/2024 | View on chart |
| ADMA | ▼ Sell | Open Market | 183,008 | $1.1M | 3/15/2024 | View on chart |
| ADMA | ▼ Sell | Open Market | 448,276 | $2.7M | 3/14/2024 | View on chart |
| ADMA | ▼ Sell | Open Market | 407,000 | $2.5M | 3/13/2024 | View on chart |
| ADMA | ▲ Buy | Grant | 24,040 | $0 | 2/26/2024 | View on chart |
| ADMA | ▲ Buy | Grant | 25,815 | $0 | 3/6/2023 | View on chart |
| ADMA | ▲ Buy | Grant | 26,586 | $0 | 3/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.